Weight-Loss Medications: What the Evidence Shows

The short answer

Semaglutide, tirzepatide, and liraglutide can produce clinically meaningful weight loss in eligible patients when used at weight-management doses. The right choice depends on medical history, side effects, access, treatment goals, and the exact approved product. This is a selected evidence review, not a systematic or comprehensive review of every weight-loss medication study. [1]

What you’ll learn

Semaglutide, tirzepatide, and liraglutide have randomized-trial evidence for weight management in eligible patients, but the drugs, doses, populations, and trial designs differ.
Dulaglutide is primarily a diabetes medicine and is not approved specifically for chronic weight management in the United States.
Counting extracted findings does not establish which medicine has the deepest overall evidence or which one is best for an individual patient.

Bottom line

Semaglutide, tirzepatide, and liraglutide can help eligible patients lose weight, but they should not be ranked by simply counting how many findings appear in a database. Trials use different doses, products, populations, comparators, and follow-up periods. Some enroll people with diabetes, while others specifically study chronic weight management.

The earlier version of this page ranked medicines by the number of extracted findings in our evidence system. That was not a comprehensive count of all studies, and a single paper could contribute several findings. We have removed the ranking.

This page reviews selected evidence. It is not a systematic or comprehensive review of every weight-loss medication trial.

Medicines covered in this review

Medicines covered in this review
Medicine	What it is used for	What matters when comparing results
Semaglutide	Certain products and doses are approved for chronic weight management; other products are approved for type 2 diabetes	Product, dose, diabetes status, follow-up, side effects, and access
Tirzepatide	Certain products are approved for chronic weight management or type 2 diabetes	Dose escalation, gastrointestinal effects, contraindications, and long-term access
Liraglutide	Available in products approved for chronic weight management or type 2 diabetes	It is injected daily rather than weekly and uses a different dose by indication
Dulaglutide	Approved for type 2 diabetes in the United States	Weight change in a diabetes trial is not the same as evidence for an obesity indication

Brand and dose matter. Results from oral semaglutide for diabetes should not be presented as if they directly describe weekly semaglutide used for chronic weight management. The same rule applies when comparing diabetes doses with obesity-treatment doses.

What the selected studies found

One cited review reported that oral semaglutide improved blood glucose and body weight compared with placebo. [1] A liraglutide study reported a greater reduction in body mass index than placebo over 12 months in participants without diabetes who had obesity. [2] A tirzepatide trial report described mean weight loss around 20% at higher doses in adults with obesity without diabetes. [3]

A comparison of dulaglutide and liraglutide in people with type 2 diabetes reported similar weight change at the studied diabetes doses. [4] That result is relevant to diabetes care, but it should not be used to rank dulaglutide alongside medicines studied and approved specifically for chronic weight management.

How clinicians choose among the options

The decision starts with eligibility and medical history. Prior pancreatitis, gallbladder disease, severe gastrointestinal symptoms, pregnancy plans, kidney risk during dehydration, and personal or family history relevant to labeled thyroid warnings can change the discussion.

Practical fit matters too. A medication may work well in a trial but be a poor long-term choice if the patient cannot access it consistently, tolerate dose escalation, eat enough protein, or protect muscle during weight loss. Midlife women may want a plan that includes resistance training, sleep, bone health, and menopause symptoms rather than focusing on the scale alone.

Safety and red flags

These medicines commonly cause nausea, vomiting, diarrhea, constipation, or abdominal discomfort. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, or signs of dehydration require prompt clinical advice. Sudden severe abdominal pain may need urgent assessment.

Weight-loss medicines are not used during pregnancy. Product labeling and contraindications differ, so the exact prescription should be reviewed rather than treating all glucagon-like peptide-1 (GLP-1) related medicines as interchangeable.

What this review includes

We retained selected cited findings but removed the unsupported evidence ranking. We did not search every database, screen all eligible trials, or grade every comparison. The page therefore describes the evidence reviewed without claiming to measure the total evidence behind each medicine.

The evidence is limited by differences in dose, product, indication, diabetes status, trial length, and follow-up. Those differences make simple study-count comparisons unreliable.

What to ask your clinician

Which exact medicine, product, and dose are you recommending, and for what indication?
What result is realistic for me, and over what period?
Which side effects or medical risks matter most in my case?
How will we protect muscle and bone while I lose weight?
What is the plan if the medicine becomes unavailable or I need to stop it?

References

[1] Gardner H, Hamdy O. Oral GLP1 Analog: Where Does the Tide Go?. Clinical Medicine Insights: Endocrinology and Diabetes. 2020;13:117955142098413. doi:10.1177/1179551420984130 https://doi.org/10.1177/1179551420984130

[2] Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis. Experimental Diabetes Research. 2012;2012:1-8. doi:10.1155/2012/672658 https://doi.org/10.1155/2012/672658

[3] Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovascular Research. 2022;119(18):2825-2842. doi:10.1093/cvr/cvac176 https://doi.org/10.1093/cvr/cvac176

[4] Wang JY, Wang QW, Yang XY, et al. GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology. 2023;14. doi:10.3389/fendo.2023.1085799 https://doi.org/10.3389/fendo.2023.1085799

Common questions

Which weight-loss medication works best?

Head-to-head evidence can inform this question, but no single answer applies to everyone. The exact product and dose, diabetes status, side effects, contraindications, access, and ability to continue treatment all matter.[1][2][3][4]

Are semaglutide and tirzepatide the same?

No. They act on different combinations of hormone receptors and use different dosing schedules. Results from one drug or dose should not be transferred to another.[1][3]

Is dulaglutide a weight-loss medication?

Dulaglutide is approved for type 2 diabetes, not specifically for chronic weight management in the United States. Some diabetes trials report weight change, but that does not make it interchangeable with an approved obesity treatment.[4]

Why was the earlier ranking removed?

It counted findings extracted into a limited evidence database, not all clinical trials. That count could not reliably measure the complete evidence behind each medication.[1][2][3][4]